Results 151 to 160 of about 23,280 (257)

Human β‐Cell Dedifferentiation and Diabetes

Journal of Diabetes, Volume 18, Issue 10, October 2026.
Human β‐cell dedifferentiation is inversely associated with HOMA‐β and occurs in Type 2 diabetes, Type 3c diabetes, and age‐related diabetes, potentially before hyperglycemia develops. Progressive loss of β‐cell identity is accompanied by dedifferentiation and transdifferentiation, suggesting that reversing these cell‐state changes may help restore ...
Jiajun Sun, Jinsook Son, Qidi Wang
wiley   +1 more source

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus

, 2009
Shannon A Miller1, Erin L St Onge2, J Roger Accardi31Pharmacotherapy Faculty, Florida Hospital East Family Practice Residency, Orlando, Florida, USA; 2University of Florida College of Pharmacy, Orlando Campus, Florida, USA; 3Accardi Clinical Pharmacy ...
Erin L St Onge, Shannon A Miller, J Roger Accardi   +2 more
core  

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Acta Psychiatrica Scandinavica, Volume 154, Issue 4, Page 305-312, October 2026.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen   +5 more
wiley   +1 more source

Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE)

, 2018
Background Ultrasonic gray-scale median (GSM) of the carotid wall reflects its composition and low-GSM carotid plaque is considered to be vulnerable.
Mitsuyoshi Takahara, Naoto Katakami, Masahiko Gosho, on behalf of the Sitagliptin Preventive study of Intima-media thickness Evaluation (SPIKE) Collaborators, Hirotaka Watada, Tomoya Mita, Yoko Irie, Taka-aki Matsuoka, Iichiro Shimomura   +8 more
core   +1 more source

Rosuvastatin-Induced Rhabdomyolysis as a Result of Drug Interaction With Sitagliptin: A Case Report

Clinical Medicine Insights: Case Reports
Rhabdomyolysis was not reported in clinical trials with Sitagliptin alone. However, several reports in the literature on rhabdomyolysis resulted from the interaction between statins and Sitagliptin. In patients with type 2 diabetes and hyperlipidemia, it
Abdolamir Atapour, Mahnaz Momenzadeh, Mahsa Panahishokouh, Shirinsadat Badri   +3 more
doaj   +1 more source

A Case of Remarkable Improvement in Dizziness and Lightheadedness in an Elderly Patient Treated With Goshajinkigan

Traditional &Kampo Medicine, Volume 13, Issue 3, December 2026.
Akiko Kikuchi, Rie Ono, Hidehisa Saito, Shin Takayama, Tadashi Ishii   +4 more
wiley   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source

Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9655-9667, October 2026.
ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu, Qi Zhang, Estefania Zapata‐Bravo, Robert W. Platt, Pauline Reynier, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Sitagliptin: New Oral Antidiabetic Agent for Tip 2 Diabetes Mellitus [PDF]

, 2011
Tip 2 Diyabet (T2DM) dünya genelinde yaygın ve hastalar hatta toplum için önemli sonuçları olan bir epidemik bir hastalıktır. T2DM için mevcut tedavi yöntemlerinin doza bağlı sınırlamaları ve yan etkileri (kilo artışı, hipoglisemi ve sindirim sistemi ...
Hazman, Ömer
core   +1 more source

Next‐Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca

ChemBioChem, Volume 27, Issue 17, 14 September 2026.
Biocatalysis is strengthening AstraZeneca's manufacture of active pharmaceutical ingredients through faster development, robust scale‐up, and lower environmental impact. Case studies illustrate where biocatalysis delivers greatest value, while enabling platforms, teams, and partnerships shape its next phase.
Alba Diaz‐Rodriguez, Martin A. Hayes, Keith R. Mulholland, Fernando Tur, Samantha Staniland   +4 more
wiley   +1 more source